Author: Gupta, Ajay; Chander Chiang, Kate
Title: Prostaglandin D(2) as a mediator of lymphopenia and a therapeutic target in COVID-19 disease Cord-id: bfof2nt1 Document date: 2020_7_21
ID: bfof2nt1
Snippet: A characteristic feature of COVID-19 disease is lymphopenia. Lymphopenia occurs early in the clinical course and is a predictor of disease severity and outcomes. The mechanism of lymphopenia in COVID-19 is uncertain. It has been variously attributed to the release of inflammatory cytokines including IL-6 and TNF-α; direct infection of the lymphocytes by the virus; and rapid sequestration of lymphocytes in the tissues. Additionally, we postulate that prostaglandin D(2) (PGD(2)) is a key meditato
Document: A characteristic feature of COVID-19 disease is lymphopenia. Lymphopenia occurs early in the clinical course and is a predictor of disease severity and outcomes. The mechanism of lymphopenia in COVID-19 is uncertain. It has been variously attributed to the release of inflammatory cytokines including IL-6 and TNF-α; direct infection of the lymphocytes by the virus; and rapid sequestration of lymphocytes in the tissues. Additionally, we postulate that prostaglandin D(2) (PGD(2)) is a key meditator of lymphopenia in COVID-19. First, SARS-CoV infection is known to stimulate the production of PGD(2) in the airways, which inhibits the host dendritic cell response via the DP(1) receptor signaling. Second, PGD(2) is known to upregulate monocytic myeloid-derived suppressor cells (MDSC) via the DP(2) receptor signaling in group 2 innate lymphoid cells (ILC2). We propose targeting PGD(2)/DP(2) signaling using a receptor antagonist such as ramatroban as an immunotherapy for immune dysfunction and lymphopenia in COVID-19 disease.
Search related documents:
Co phrase search for related documents- acute sars cov infection and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars cov infection and adaptive innate immune response: 1, 2, 3, 4, 5, 6
- acute sars cov infection and lymph node: 1, 2, 3, 4, 5
- acute sars cov infection and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute sars cov infection and lymphocytic infiltration: 1
- acute sars cov infection and lymphoid cell: 1
- acute sars cov infection and lymphopenia common: 1
- adaptive immune response and lymph node: 1, 2, 3, 4, 5, 6
- adaptive immune response and lymph node drain: 1
- adaptive immune response and lymphocyte count: 1
- adaptive immune response and lymphoid cell: 1, 2
- adaptive immune response and lymphoid cell innate: 1
- adaptive innate and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive innate and lymphocyte count: 1, 2
- adaptive innate and lymphoid cell: 1, 2, 3, 4, 5, 6, 7
- adaptive innate and lymphoid cell innate: 1, 2, 3, 4
- adaptive innate immune response and lymphoid cell: 1, 2
- adaptive innate immune response and lymphoid cell innate: 1
Co phrase search for related documents, hyperlinks ordered by date